^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Cancer

    Related cancers:
    1d
    Effects of Pranayama Breathing Technique on Stress Level, Sleep Quality, and Quality of Life Among Older Adults (clinicaltrials.gov)
    P=N/A, N=74, Completed, Namik Kemal University
    New trial • HEOR
    1d
    Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    1d
    A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Keytruda (pembrolizumab) • trastuzumab brengitecan (BL-M07D1)
    1d
    XmAb819-01: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=307, Recruiting, Xencor, Inc. | N=95 --> 307 | Trial completion date: Nov 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    HEROS: Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Gruppo Oncologico Italiano di Ricerca Clinica | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    1d
    Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens (clinicaltrials.gov)
    P=N/A, N=160, Recruiting, Brigham and Women's Hospital | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    1d
    DK222 Study at Hopkins (clinicaltrials.gov)
    P1, N=6, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    1d
    AcceleRET Lung: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).
    Trial termination
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)
    1d
    An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Peking Union Medical College Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Qibeian (iparomlimab/tuvonralimab)
    1d
    U31402-A-U102: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=312, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X • KRAS G12
    |
    patritumab deruxtecan (U3-1402)
    1d
    The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (clinicaltrials.gov)
    P=N/A, N=8000, Recruiting, UMC Utrecht | Trial completion date: May 2025 --> Aug 2030 | Trial primary completion date: Feb 2024 --> Feb 2030
    Trial completion date • Trial primary completion date
    1d
    STC-15-24202: STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers (clinicaltrials.gov)
    P1/2, N=188, Recruiting, STORM Therapeutics LTD | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • STC-15